Ninlaro (ixazomib) vs Empliciti (elotuzumab)

Ninlaro (ixazomib) and Empliciti (elotuzumab) are both used in the treatment of multiple myeloma, but they work in different ways: Ninlaro is an oral proteasome inhibitor that helps to block the breakdown of proteins in cancer cells, leading to cell death, while Empliciti is an intravenous monoclonal antibody that targets and flags myeloma cells for the immune system to attack. Ninlaro is often used in combination with lenalidomide and dexamethasone, and its oral administration may be convenient for patients, whereas Empliciti is combined with lenalidomide and dexamethasone as well but requires infusion at a healthcare facility. The choice between these medications would depend on the individual's specific medical condition, treatment history, and preference for oral versus intravenous administration, as well as the side effect profile and the recommendation of their healthcare provider.

Difference between Ninlaro and Empliciti

Metric	Ninlaro (ixazomib)	Empliciti (elotuzumab)
Generic name	Ixazomib	Elotuzumab
Indications	Multiple myeloma	Multiple myeloma
Mechanism of action	Proteasome inhibitor	SLAMF7-directed immunostimulatory antibody
Brand names	Ninlaro	Empliciti
Administrative route	Oral	Intravenous
Side effects	Thrombocytopenia, gastrointestinal toxicities, peripheral neuropathy, edema, rash	Infusion reactions, lymphocytopenia, hyperglycemia, electrolyte abnormalities, diarrhea
Contraindications	Hypersensitivity to ixazomib or any of its excipients	Hypersensitivity to elotuzumab or any of its excipients
Drug class	Proteasome inhibitor	Monoclonal antibody
Manufacturer	Takeda Oncology	Bristol-Myers Squibb

Efficacy

Ninlaro (Ixazomib) Efficacy in Multiple Myeloma

Ninlaro (ixazomib) is an oral proteasome inhibitor that is approved for the treatment of multiple myeloma in combination with lenalidomide and dexamethasone. This combination is indicated for patients who have received at least one prior therapy. The efficacy of ixazomib was demonstrated in the pivotal phase 3 clinical trial known as TOURMALINE-MM1. In this study, patients treated with ixazomib in combination with lenalidomide and dexamethasone had a significantly longer progression-free survival (PFS) compared to those who received placebo with lenalidomide and dexamethasone. The median PFS was 20.6 months in the ixazomib group compared to 14.7 months in the placebo group, highlighting the benefit of adding ixazomib to the treatment regimen for multiple myeloma patients.

Empliciti (Elotuzumab) Efficacy in Multiple Myeloma

Empliciti (elotuzumab) is a monoclonal antibody that targets the SLAMF7 protein, which is expressed on myeloma cells and certain immune cells. It is approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one to three prior therapies. The efficacy of elotuzumab was established in a phase 3 study known as ELOQUENT-2. In this trial, patients receiving elotuzumab in addition to lenalidomide and dexamethasone demonstrated a significant improvement in PFS compared to those receiving lenalidomide and dexamethasone alone. The median PFS was 19.4 months in the elotuzumab group versus 14.9 months in the control group.

Both Ninlaro and Empliciti have shown to be effective in improving outcomes for patients with multiple myeloma when used in combination with other therapies. Their use is a reflection of the evolving treatment landscape in multiple myeloma, which increasingly involves combination therapies aimed at targeting the disease from different angles to improve patient response and survival rates. It is important to note that the choice of therapy should be individualized based on the patient's previous treatments, response to therapy, and overall health status.

As with any medication, the efficacy of Ninlaro and Empliciti can vary among individuals, and potential side effects should be carefully considered. Healthcare providers should monitor patients for adverse reactions and make treatment adjustments as necessary. Patients should engage in open dialogue with their healthcare team to understand the potential benefits and risks associated with these medications.

Regulatory Agency Approvals

Ninlaro

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Empliciti

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Access Ninlaro or Empliciti today

If Ninlaro or Empliciti are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Ninlaro

Buy Empliciti

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: